SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-039517
Filing Date
2023-11-06
Accepted
2023-11-06 16:05:38
Documents
14
Period of Report
2023-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 40936
2 ex99-1.htm EX-99.1 90832
3 ex99-1_001.jpg GRAPHIC 4302
  Complete submission text file 0001493152-23-039517.txt   321702

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE indp-20231106.xsd EX-101.SCH 3021
5 XBRL LABEL FILE indp-20231106_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE indp-20231106_pre.xml EX-101.PRE 22363
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3227
Mailing Address 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY 10019
Business Address 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY 10019 (646) 427-2727
Indaptus Therapeutics, Inc. (Filer) CIK: 0001857044 (see all company filings)

IRS No.: 863158720 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40652 | Film No.: 231379968
SIC: 2834 Pharmaceutical Preparations